# US 2006/0154919 A1 · Combination of a glycine transporter (GLYT1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154919 A1
- Document ID: US20060154919A1
- Status: Published application
- Kind: A1
- Application number: 11/304,175
- Filed: 2005-12-15
- Published: 2006-07-13
- Earliest claimed: 2004-12-16
- Inventors: John Moyer; David Ashton; Peter Kalivas; Mark Klitenick
- Web page: https://patentgrep.com/patent/US20060154919A1

## CPC

- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/381: having five-membered rings
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An antipsychotic and GlyT1 inhibitor combination is disclosed. The antipsychotic and GlyT1 inhibitor combination may be employed in the prevention and treatment of symptoms of schizophrenia. Pharmaceutical compositions and treatments comprising an antipsychotic and a GlyT1 inhibitor for treating symptoms of schizophrenia are thus also disclosed.

## Claims

### Claim 1

A method of treating or preventing a symptom of schizophrenia in a mammal, comprising administering an antipsychotic and a GlyT1 inhibitor to said mammal in an amount effective to treat or prevent said symptom of schizophrenia.

### Claim 2

A method of increasing extracellular glycine in a mammal, comprising administering an antipsychotic and a GlyT1 inhibitor to said mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein said extracellular glycine is increased to an amount more than if said antipsychotic or said GlyT1 inhibitor was administered alone.

### Claim 4 (depends on 2)

The method of claim 2, wherein said GlyT1 inhibitor has minimal or no effect on extracellular dopamine.

### Claim 5

A medical product, comprising (a) an antipsychotic, and (b) a GlyT1 inhibitor, as a combined preparation for simultaneous, separate or sequential use in treating or preventing a disorder that can present a symptom of schizophrenia.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the antipsychotic is selected from the group consisting of olanzapine, haloperidol, fluphenazine, chlorpromazine, clozapine, risperidone, paliperidone, R209130, aripiprazole, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable esters thereof and enantiomeric forms thereof.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the GlyT1 inhibitor is selected from the group consisting of:
and pharmaceutically acceptable salts thereof, pharmaceutically acceptable esters thereof and enantiomeric forms thereof.

### Claim 8 (depends on 3)

The method according to claim 3 wherein the antipsychotic is selected from the group consisting of olanzapine, haloperidol, fluphenazine, chlorpromazine, clozapine, risperidone, paliperidone, aripiprazole, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable esters thereof and enantiomeric forms thereof.

### Claim 9

A process for treating a psychotic disease in a mammal, comprising administering to said mammal an antipsychotic and a GlyT1 inhibitor in an amount effective to treat or prevent the clinical manifestations of said psychotic disease.

### Claim 10 (depends on 9)

The process of claim 9 wherein the psychotic disease is selected from the group consisting of schizophrenia, dementia, depression, Alzheimer's, ADHD, substance abuse and anxiety.
